logo
Don't let the season go by without making strawberry shortcake

Don't let the season go by without making strawberry shortcake

On a recent visit to see my son at the University of California, Davis, I wandered into a lab at the Robert Mondavi Institute for Wine and Food Science … as one does. A bunch of students were preparing for a tasting to evaluate some of the strawberry breeds they have been developing.
My food nerd heart swelled, and for the first time in decades, I missed school.
When strawberries are in season, it is incumbent upon us to make the most of those fleeting weeks.
And I can't think of a better way to put them to use than in a classic strawberry shortcake. If you can find wild strawberries, or at least really flavorful ones from a farmers market (or if you are getting your PhD in food studies with a concentration in strawberries in California), this treat is nothing short of heavenly.
There is nothing difficult about strawberry shortcake. A few components come together in a gorgeous stack of sweetness.
First, the biscuitsI like my shortcake biscuits slightly sweet, but not overly sugary. The natural sweetness in the sliced strawberries will be augmented with a bit of sugar to amp up those ruby red juices. Plus there's the whipped cream, which can be as sweet or restrained as you like.
Cut out the biscuits as close together as you can, with as little dough left behind on the cutting board as possible. Yes, you can roll the scraps up and cut out another couple of circles, but the more you handle the dough the less tender it becomes.
The tops of the biscuits are brushed with a bit of half-and-half or milk and sprinkled with sugar before they go into the oven, resulting in a beautifully browned and slightly crunchy top.
Make biscuits with some height to them, as you will be cutting them horizontally and then filling them with the strawberries and cream.
The layersI like a double-decker strawberry shortcake, which definitely requires a knife and fork.
To assemble: The bottom half of the biscuit goes first, then some whipped cream, then strawberries. Then the top half of the biscuit. And then, yes, more whipped cream and more strawberries.
The addition of sour cream to the whipped cream is a pastry chef hack that I learned over the years. It adds more richness, stability and body to the whipped cream, and gives the whole shebang a whole other layer of lushness.
Strawberry ShortcakeServes 6
Ingredients:2 ½ cups all-purpose flour, sifted
6 tablespoons granulated sugar, divided
4 teaspoons baking powder
½ teaspoon baking soda
1 teaspoon kosher salt
Finely grated zest of 1 lemon
¾ cup (1 ½ sticks) cold unsalted butter, cut into small cubes
¾ cup half-and-half or whole milk
2 tablespoons melted butter
2 pints (4 cups) fresh strawberries, hulled and sliced
For the Whipped Cream:
1 cup heavy cream, chilled
2 tablespoons sour cream, crème fraiche or mascarpone (optional)
2 tablespoons confectioners' sugar
1 teaspoon pure vanilla extract
Directions:1. Preheat the oven to 425°F. Very lightly flour a clean counter or work surface.
2. Combine the flour with 2 tablespoons of the granulated sugar, the baking powder, baking soda, salt, and lemon zest in a medium bowl. Cut in the butter with a pastry blender or use your fingers to rub it into the flour until the mixture resembles coarse crumbs. Or, pulse the butter into the flour mixture in a food processor.
3. Add the ¾ cup half-and-half or milk and stir until just barely combined. Turn the mixture onto the lightly floured surface. Use your hands to lightly mix the dough until it barely holds together. Pat it out into a circle or a rectangle 1/2-inch thick.
4. Use a 3-inch round biscuit or cookie cutter to cut out the shortcakes, keeping them as close together as possible to minimize extra dough. Use a sharp biscuit cutter rather than a glass, and press down and pull straight up, without twisting; twisting will hinder their rising as they bake. If you dip the biscuit cutter in flour between each biscuit cutting, it will help prevent sticking. Collect the scraps and re-pat them out into a ½-inch disk, and cut out another 2 or 4 circles when you are done. Try to handle the dough as little as possible.
5. Butter a baking sheet or spray it with nonstick cooking spray. Transfer half the biscuits to the sheet. Brush the tops with a bit of the melted butter. Top the butter-brushed dough with the remaining cut-out biscuits. Brush the tops with a bit of milk or half-and-half. Sprinkle 2 tablespoons of sugar over the shortcakes.
6. Bake for about 15 minutes, until light golden brown. Transfer to a wire rack to cool.
7. Meanwhile, put the berries in a medium bowl and sprinkle with the remaining 2 tablespoons of sugar, or to taste. Toss with a fork, and lightly crush some of the berries so you have some different textures going on and some of the juices are released. Let the berries sit for at least 15 minutes.
8. Once the berries are macerating, make the whipped cream. Place the heavy cream, sour cream, confectioners' sugar and vanilla in a clean bowl (if you chill it first, the cream will whip up faster.)
9. Use a whisk or a handheld electric mixer on high speed to beat the cream until it starts to form stiff peaks. Refrigerate until ready to use.
10. Just before serving, cut each biscuit crosswise. Place the bottom halves on plates, layer on some strawberries, then some whipped cream. Replace the top of the shortcake, then spoon over some more strawberries and whipped cream. Serve immediately.
___
Katie Workman writes regularly about food for The Associated Press. She has written two cookbooks focused on family-friendly cooking, 'Dinner Solved!' and 'The Mom 100 Cookbook.' She blogs at https://themom100.com/. She can be reached at [email protected].
___
For more AP food stories, go to https://apnews.com/hub/recipes.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead dives into ‘in vivo' cell therapy with $350M buyout of Interius
Gilead dives into ‘in vivo' cell therapy with $350M buyout of Interius

Yahoo

timean hour ago

  • Yahoo

Gilead dives into ‘in vivo' cell therapy with $350M buyout of Interius

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Gilead Sciences is deepening its investment in cancer cell therapy, announcing Thursday a deal to pay $350 million to buy privately held Interius BioTherapeutics for a technology designed to reprogram immune cells in patients' bodies. If successful, Interius' 'in vivo' approach could yield a simpler alternative to the CAR-T therapies Gilead's Kite Pharma division have brought to market, each of which includes extravagant production processes that involve manipulating cells in a lab. Gilead spent $12 billion to buy Kite nearly a decade ago and, since then, has become a leader in CAR-T therapies. That business has sputtered recently amid declining demand and competition from other developers. But Gilead is still investing through acquisitions and partnerships, such as a collaboration with Arcellx in multiple myeloma. Dive Insight: Cell therapies are something of a double-edged sword. They can powerfully drive cancers into a deep and long-lasting remission, but carry potentially serious safety risks and a burdensome chemotherapy 'conditioning' step. A complex manufacturing process in which a patient's cells are shipped to a lab, modified, and reinfused, limits CAR-T's reach, too. Drugmakers have long tried to simplify the process in one way or another, with limited success. But one approach that's gained traction is so-called in vivo cell therapy, through which companies use technological tools like gene editing or messenger RNA to rewire cells inside the body. Several in vivo cell therapy developers have sprung up in recent years. While their work remains early, they've started to draw the interest of large pharmaceutical companies. AstraZeneca bought startup EsoBiotech in March and, in June, AbbVie followed with a deal for another privately held company, Capstan Therapeutics. Now Gilead has embraced the approach in acquiring Interius, which uses engineered viruses to deliver into certain immune cells instructions for cancer-targeting protein receptors. An experimental drug called INT2104 it's developing is among the first in vivo cell therapies to be tested in humans. An ongoing Phase 1 study is evaluating it in certain blood cancers. The company has also been conducting early research in autoimmune diseases, as well as a third, undisclosed project. The deal 'marks a pivotal step for Interius and the future of in vivo therapy, which has the potential to reduce treatment timelines, broaden access to care and improve outcomes for patients with aggressive or advanced disease,' said Interius CEO Phil Johnson, in a statement. Interius spun out of the University of Pennsylvania in 2021 and raised a $76 million Series A round that year. Gilead will use cash to purchase Interius' shares, which the company said will reduce its 2025 per-share earnings by 23 to 25 cents. Sign in to access your portfolio

Premier Select Sires Inc. and Native Microbials Inc. Partner to Bring Dairy Producers the Next Technology in Genetic Improvement
Premier Select Sires Inc. and Native Microbials Inc. Partner to Bring Dairy Producers the Next Technology in Genetic Improvement

Yahoo

timean hour ago

  • Yahoo

Premier Select Sires Inc. and Native Microbials Inc. Partner to Bring Dairy Producers the Next Technology in Genetic Improvement

Premier Select Sires will distribute Native Microbials' Galaxis™ Frontier, a product that improves rumen genetics to enable healthier and higher producing cows, in the Eastern U.S. TUNKHANNOCK, Pa. and SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- Premier Select Sires Inc. and Native Microbials Inc. are excited to announce a partnership to help dairy producers improve the health and performance of their cows. The agreement enables Premier Select Sires to sell and distribute Galaxis Frontier, Native Microbials' flagship rumen genomics solution, proven to significantly improve herd health and productivity by optimizing the genetics in the rumen of dairy cows. Native Microbials gains the sales support and distribution in the eastern U.S., while Premier Select Sires obtains a revolutionary new rumen-focused genomics technology to provide to their customer base. Galaxis Frontier is the only anaerobic rumen microbial consortia containing four native-rumen species that perform essential biochemical functions in the rumen of dairy cows. Farmers using Galaxis Frontier have claimed significant benefits, including increased colostrum yield, reduced early culling and metabolic disease, improved feed efficiency, and significant gains in milk yield and energy-corrected milk (ECM) through higher peaks and greater persistency. Research in both academic and commercial settings has also demonstrated positive effects on immune function, energy metabolism, and mammary development. Premier Select Sires is a farmer-owned cooperative committed to providing its members with access to industry-leading genetics and herd management products. For nearly 90 years, the cooperative's genetic improvement has centered around selective breeding, artificial insemination, and advanced reproductive technologies. Now, Premier is excited to partner with Native Microbials to go a step further, unlocking new potential by controlling and improving the genetic makeup of the rumen environment through this product that can be fed to dairy cattle. "Producers may be surprised to know that there are a lot more opportunities to influence the performance of a bovine through the genetics of the rumen microbes than the actual bovine genome," said Kirk Sattazahn, Vice President of Marketing and Development for Premier Select Sires. "We have always had success focusing on genetic improvement of the cow and now Galaxis Frontier allows us to have a more immediate genetic impact on the rumen. The rumen is the power unit of the cow, and it makes sense to influence health and production right at the source. We are very excited to bring this technology with proven research and development to our customers." Michael Seely, co-founder and CEO of Native Microbials, said "At Native Microbials, microbial genomics is the foundation of everything we do. We identify and develop novel environmental microbes based on their genetic capacity to enhance the productivity, health, and efficiency of animals. Our scientific platform is entirely focused on the ability of a microbe and its genes to make a difference for customers and animals. Our data consistently shows that reintroducing higher concentrations of the highest performing rumen genomes back into the rumen habitat reshapes the rumen microbial community, enabling superior outcomes for the cow." Beginning in September 2025, dairy producers will be able to order Galaxis Frontier from their Premier Select Sires sales reps. Galaxis Frontier is currently marketed direct to farm, with a strong customer footprint in California's Central Valley, the Pacific Northwest, Rocky Mountains, and the Midwest. The expansion to the eastern U.S. is critical to unlocking technology access to producers in this important dairy geography. "I'm excited to work with our team of sales professionals to bring this innovative and pioneering technology to our member owners," said Jeff Hostetter, Product Manager for Premier Select Sires. "Just like bovine genomics changed the dairy industry by enabling more precise and rapid genetic progress, the utilization of rumen genomics will be a catalyst to optimize the efficiency and production of our dairy cattle." Seely added, "We're proud to partner with Premier Select Sires, whose expertise in bovine genetics has transformed dairy herds for many years. Together, we're expanding the application of genetics from the bovine genome to the rumen microbiome. This new layer of genomic precision will help dairy farmers improve profitability while supporting healthier and more sustainable herds." To learn more about Galaxis Frontier and hear from current customers, visit Orders may be placed through any Premier Select Sires representative. To get in contact with your local representative, please visit © 2025 Native Microbials, Inc. All rights reserved.© 2025 Premier Select Sires, Inc. All rights reserved. View original content to download multimedia: SOURCE Native Microbials Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines
AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines

Yahoo

timean hour ago

  • Yahoo

AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines

SEATTLE, August 21, 2025--(BUSINESS WIRE)--Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world. Under this strategic alliance, Quratis has been selected as AAHI's preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies, with the capacity to expand into commercial-scale production for global markets. This collaboration will accelerate the development of AAHI's innovative vaccine candidates targeting deadly diseases such as tuberculosis, and of vaccines that rely on AAHI's vaccine adjuvants to provide protection against malaria, HIV, and other global health threats. Quratis brings a world-class GMP-certified bioplant and cutting-edge CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. By designating Quratis as preferred partner, AAHI strengthens both its scientific capabilities and access to scalable, cost-effective production of its groundbreaking vaccine formulations—including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection. The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world's most vulnerable populations. "Partnering with Quratis is a very important step in AAHI's strategy to advance practical, life-saving vaccines, that can be deployed at scale where they're needed most," said Keeley Foley, CEO of AAHI. "Quartis' innovative cutting edge, safe, world-class CDMO capabilities makes it possible for AAHI to deliver on our mission – and helps ensure our efforts to combat infectious diseases and foster health autonomy worldwide. Together, we're not just manufacturing vaccines—we're delivering an important mission to revolutionize global health." Quratis, renowned for its global innovation in healthcare, brings unparalleled expertise in vaccine development and manufacturing to the table. With a track record of success in TB and COVID-19 vaccines like QTP101 and QTP104, Quratis' advanced processes will enhance AAHI's pipeline, ensuring high-quality, efficient production from pre-clinical stages through clinical trials. "We are honored and thrilled to join forces with AAHI, a pioneer in immune-enhancing technologies and sustainable vaccine solutions," said Soung Joon Kim, CEO of Quratis. "This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI's pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities." The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis vaccine candidate (QTP101), and underscores a shared commitment to strengthening international vaccine supply chains, advancing equitable access, and fostering worldwide manufacturing capacity for sustainable program deployment. For more information about this partnership or to explore collaboration opportunities, and order pre clinical materials please contact info@ About Access to Advanced Health Institute (AAHI) Access to Advanced Health Institute (AAHI) is a global leader in developing practical, cost-effective vaccines to combat deadly diseases such as tuberculosis, malaria, and HIV. With a mission to translate high-impact science into scalable, field-ready solutions, AAHI breaks through barriers in global health by creating innovative vaccine formulations, building worldwide manufacturing capacity, and fostering partnerships to ensure sustainable, equitable health outcomes. For more information, visit or contact us at info@ About Quratis Quratis Inc. is a leading biopharmaceutical company specializing in innovative vaccine development and advanced biologics manufacturing. With a state-of-the-art GMP facility and strong global partnerships, Quratis is at the forefront of developing next-generation vaccines against infectious diseases, including tuberculosis, COVID-19, schistosomiasis, and neglected tropical diseases. In addition to its core vaccine pipeline, Quratis offers superior CDMO capabilities, including expertise in mRNA–LNP drug delivery platforms that provide seamless bench-to-field support from research through commercial production. By combining cutting-edge R&D with scalable manufacturing, Quratis is committed to delivering high-quality, accessible, and life-saving solutions to patients worldwide. For more information, visit View source version on Contacts Casey Felipeinfo@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store